Talk:Sunovion

message: :Image:Sepracor logo.gif is being used on this article. I notice the image page specifies that the image is being used under fair use but there is no explanation or rationale as to why its use in this Wikipedia article constitutes fair use. In addition to the boilerplate fair use template, you must also write out on the image description page a specific explanation or rationale for why using this image in each article is consistent with fair use.
Please go to the image description page and edit it to include a fair use rationale. Using one of the templates at Wikipedia:Fair use rationale guideline is an easy way to insure that your image is in compliance with Wikipedia policy, but remember that you must complete the template. Do not simply insert a blank template on an image page.
If there is other other fair use media, consider checking that you have specified the fair use rationale on the other images used on this page.  Note that any fair use images uploaded after 4 May, 2006, and lacking such an explanation will be deleted one week after they have been uploaded, as described on criteria for speedy deletion. If you have any questions please ask them at the Media copyright questions page. Thank you.BetacommandBot 04:09, 6 June 2007 (UTC)
thread_title: Fair use rationale for Image:Sepracor logo.gif

message: Apparently, Sepracor has developed a drug entitled Brovana with the purpose of fighting COPD. This drug should probably be mentioned in the main article seeing as it constitutes a major drug in the company's pipeline of products. FitzColinGerald 13:45, 6 July 2007 (UTC)
thread_title: Brovana

message: How is it that the Lunesta article is far more developed than the Sepracor article? FitzColinGerald 07:45, 19 September 2007 (UTC)
thread_title: Lunesta article

message: This article has recently incurred a large influx of biased and superfluous information. Such material has no place in an encyclopedic article. Examples include:Apparently the challenging economic times do not apply to him [Adrian Adams - CEO]. He is viewed as an arrogant and dictatorial person. He and upper management at Sepracor are in vast discord with sales and marketing and large numbers of talented individuals have left the company due to the managerial arrogance and dictatorial style. And,In view of the string of bad news over the past 24 months and weak sales of its flagship products XOPENEX and LUNESTA, it is another example of managerial duplicity and inimical treatment of the rest of the company. Many wonder how long this managerial impotence and financial obscenity will last.In referring to Wikipedia's guidelines regarding neutral point of view, one will see that this kind of language is simply unacceptable. FitzColinGerald (talk) 14:11, 28 May 2009 (UTC)
thread_title: NPOV and Extemporaneous Information

message: Given the company's recent name change, this article should probably be renamed "Sunovion." FitzColinGerald (talk) 18:18, 1 December 2010 (UTC)
thread_title: Name Change

message: Hello,
I am a Sunovion employee and would like to help update the Wikipedia entry for the company. There are some inaccuracies and additions that are needed that I would like to work with you on to ensure I am updating them properly and according to Wikipedia guidelines.
I look forward to working with you. ThanksEd at Sunovion (talk) 17:13, 25 November 2019 (UTC)
thread_title:  Sunovion - edits 

message: Hello,  
I am a Sunovion employee and I've detailed out below some edits that I would like to implement on this page. 
In the title for the page and infobox there is no comma in Sunovion Pharmaceuticals Inc.  and it should be removed.
In the infobox under ‘Key people,’ remove ‘Nobuhiko Tamura (Chairman and CEO)’. This should read ‘Antony Loebel, M.D. (President and CEO)’. 
For the ‘Products’ section of the infobox, remove ‘Omnaris, Alvesco, Zetonna’ as these products have been divested. Add new and acquired products ‘Longhala Magnair, Arcapta Neohaler, Seebri Neohaler, Utibron Neohaler’.
The ‘Parent’ products section of the infobox should read ‘Sumitomo Dainippon Pharma’.
In paragraph one of ‘Company history’, in the second to last sentence, add ‘(COPD)’ after ‘chronic obstructive pulmonary disease’. Also, remove the last unsubstantiated sentence in paragraph one ‘All of the launch drugs were manufactured under the leadership of Walter Piskorski.’ Then, add to paragraph one ‘Brovana® (Arfomoterol Tartrate) was then approved by the FDA to treat COPD on October 6, 2006. [3]’ 
The source for this new sentence is Company press release https://www.businesswire.com/news/home/20061006005585/en/FDA-Approves-Sepracors-BROVANA-TM-Arformoterol-Tartrate
In ‘Company history’, add second paragraph ‘In October 2010 the FDA approved once-daily Latuda®  (lurasidone HCL) for the treatment of adults with schizophrenia.[4]  The FDA went on to approve Latuda (lurasidone HCL) as a monotherapy and adjunctive therapy with either lithium or valproate to treat adults with major depressive episodes associated with bipolar I disorder (bipolar depression) in July 2013. [5]‘ 
The sources for this paragraph are https://www.fiercebiotech.com/biotech/fda-approves-once-daily-latuda%C2%AE-lurasidone-hcl-for-treatment-of-patients-schizophrenia and https://www.boston.com/news/innovation/2013/07/03/fda-approves-sunovions-latuda-to-treat-some-cases-of-bipolar-disorder
In ‘Company history’, add paragraph three ‘The FDA approved Aptiom® (eslicarbazepine acetate) as an adjunctive therapy for partial-onset seizures associated with epilepsy in adults in November of 2013.[6] Aptiom was later FDA approved for the treatment of children and adolescents with epilepsy aged 4-17 years.[7]‘
The sources for this paragraph are https://www.medscape.com/viewarticle/814116 and https://www.neurologyadvisor.com/topics/epilepsy/fda-approves-expanded-seizure-indication-for-aptiom/
For paragraph four ‘Sunovians’ should be spelled ‘Sunovion’s’. 
Add paragraph five ‘Also in 2016, Sunovion entered a license agreement with Novartis for U.S. commercialization rights to Utibron® Neohaler (indacaterol and glycopyrrolate), Seebri® Neohaler (glycopyrrolate) and Arcapta® Neohaler (indacaterol) for the long-term, maintenance treatment of airflow obstruction in people with COPD.[9]‘ 
The source for this paragraph is https://www.drugdeliverybusiness.com/sunovion-novartis-ink-licensing-deal-inhaled-copd-drugs/
Add paragraph six ‘Later, in January 2017, Latuda received FDA approval to treat adolescents (aged 13-17 years) with schizophrenia.[10] The FDA additionally approved Latuda for the treatment of major depressive episodes associate with bipolar I disorder (bipolar depression) in children and adolescents aged 10-17 years in March 2018.[11]’
The sources for this paragraph are https://www.medscape.com/viewarticle/875102 and https://www.medscape.com/viewarticle/893542
Add paragraph seven ‘In December 2017, Sunovion announced that the FDA approval of Lonhala® Magnair® (glycopyrrolate) Inhalation Solution for the treatment of COPD. [12]’
The source for this paragraph is https://copd.net/news/lonhala-magnair-receives-fda-approval
In the section ‘Acquisition by Dainappon Sumitomo’ change ‘Dainappon Sumitomo’ to correct company name ‘Sumitomo Dainippon Pharma’ in the title and first sentence. 
In this section, also change ‘Dainappon Sumitomo’ in sentences two and three to ‘the company’
Then in the last sentence of this section change ‘Dainippon Sumitomo Pharma’ to ‘Sumitomo Dainippon Pharma’
In the ‘Beneficiaries, partners, and subsidiaries’ section add this setnecne to the end of the paragraph ‘The company announced in 2017 it had entered into a definitive agreement to divest the U.S. market rights to Alvesco, Omnaris, and Zetonna to Covis Pharma B.V.’
The source for this sentence is https://www.drugdeliverybusiness.com/sunovion-divests-asthma-allergy-tech-covis-pharma/
Thanks for your help Ed at Sunovion (talk) 18:01, 25 November 2019 (UTC)
thread_title: Some proposed changes

message: #  The changes to the infobox, including punctuation, the removal of a former executive, and the removal of products, were implemented.
#  The new products were not implemented, as the Wikilinks for those articles were not included with the request.
#  The misspelling of a possessive noun (Sunovion's) in the main prose was not corrected, as that portion of the sentence was removed.
#  Walter Piskorski was removed as manufacturer in the Company history section.
#  The acronym COPD was added to the Wikilink.
#  The subsequent claims proposed to be added were not implemented, as the references to this information are based on company-issued press releases. Please provide references from reliable, independent, WP:SECONDARY sources for these claims.
* The names of non-notable individuals involved in the development of certain drugs were omitted.
* Unreferenced information in portions of the main text were omitted.
* The information under the Acquisition by Sumitomo section which described the "halting of trading" before the Sumitomo announcement, the stock price / shares change, and other irrelevant information was omitted. 
Regards,  Spintendo  20:44, 25 November 2019 (UTC)
thread_title: Reply 25-NOV-2019

message: Hello,  
I am a Sunovion employee and would like to help update the Wikipedia entry for the company. There are additions that are needed that I would like to work with you on to ensure I am updating them properly and according to Wikipedia guidelines.
I look forward to working with you. ThanksEd at Sunovion (talk) 21:08, 4 December 2019 (UTC)
thread_title:  Sunovion - additional edits  

message: Hello,  
I am a Sunovion employee and I’ve detailed out below some edits that I would like to implement on this page. I have added WikiLinks and secondary sources for consideration. 
For the ‘Products’ section of the infobox, add new and acquired products ‘Longhala Magnair, Arcapta Neohaler, Seebri Neohaler, Utibron Neohaler’.
The WikiLinks sources for this section are https://en.wikipedia.org/wiki/Indacaterol/glycopyrronium_bromide for Lonhala Magnair, Seebri Neohaler, Utibron Neohaler and https://en.wikipedia.org/wiki/Indacaterol for Arcapta Neohaler
The ‘Parent’ products section of the infobox should read the correct company name ‘Sumitomo Dainippon Pharma’.
In ‘Company history’, add paragraph two ‘In October 2010 the FDA approved once-daily Latuda®  (lurasidone HCL) for the treatment of adults with schizophrenia.[4]  The FDA went on to approve Latuda (lurasidone HCL) as a monotherapy and adjunctive therapy with either lithium or valproate to treat adults with major depressive episodes associated with bipolar I disorder (bipolar depression) in July 2013. [5]‘ 
The sources for this paragraph are https://psychcentral.com/news/2010/10/28/latuda-approved-to-treat-schizophrenia/20351.html and https://www.boston.com/news/innovation/2013/07/03/fda-approves-sunovions-latuda-to-treat-some-cases-of-bipolar-disorder
In the section ‘Acquisition by Dainappon Sumitomo’ change ‘Dainappon Sumitomo’ to correct company name ‘Sumitomo Dainippon Pharma’ in the title and first sentence. 
Thanks for your help Ed at Sunovion (talk) 22:08, 4 December 2019 (UTC)
thread_title: Additional proposed changes

message: * The name of the acquiring company is taken directly from that company's Wikipedia page. This article uses that name.
* The products could not be added, because the Wikilinked articles do not confirm that these products contain those ingredients. 
* The information about lurasidone could not be added because the proposed text does not make clear Sunovion's relationship as a marketer of the drug under its newer FDA indicated-use, rather than as a developer. That nuance needs to be made clear to readers if this information is to be added.
Regards,  Spintendo  09:08, 5 December 2019 (UTC)
thread_title: Reply 05-DEC-2019

message: Hello,  
I am a Sunovion employee and I’ve detailed below some edits that I would like to implement on this page. I have added WikiLinks and sources for consideration. 
In ‘Company history’ add as the last sentence in paragraph one ‘In October 2006, Brovana (Arfomoterol Tartrate) was then approved by the FDA to be marketed by Sunovion to treat COPD. [3]’
The source for this paragraph is  https://en.wikipedia.org/wiki/Arformoterol 
In ‘Company history’, add paragraph two ‘In October 2010 the FDA approved once-daily Latuda (lurasidone HCL) for the treatment of adults with schizophrenia and Sunovion received approval to market the drug.[4] Sunovion then received regulatory FDA approval to sell Latuda (lurasidone HCL) as a monotherapy and adjunctive therapy with either lithium or valproate to treat adults with major depressive episodes associated with bipolar I disorder (bipolar depression) in July 2013. [5]‘
The sources for this paragraph are https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171824/ and https://en.wikipedia.org/wiki/Lurasidone
In ‘Company history’, add paragraph three ‘In November of 2013, the FDA approved Aptiom (eslicarbazepine acetate) to be marketed by Sunovion as an adjunctive therapy for partial-onset seizures associated with epilepsy in adults.[6]’ 
The sources for this paragraph are https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/ and https://en.wikipedia.org/wiki/Eslicarbazepine_acetate 
Thanks for your help Ed at Sunovion (talk) 21:57, 22 January 2020 (UTC)
thread_title: Additional proposed changes

message: * The references provided with the request are addressed below:
# Proposals where Wikipedia is listed as the reference - please see WP:WINARS.
# The NCBI article on Aptiom does not mention Sunovion by name.
# The NCBI article on Latuda only lists Sunovion in reference to the drug's PI. The other claims in the proposed addition are not handled by the NCBI source.
Regards,  Spintendo  10:47, 26 January 2020 (UTC)
thread_title: Reply 26-JAN-2020

message: Hello,  
I am a Sunovion employee and would like to help update the Wikipedia entry for the company. For consideration, here’s a revised addition based off of editor feedback with sources. 
In ‘Company history’, add paragraph two ‘In October 2010 the FDA approved once-daily Latuda (lurasidone HCL) for the treatment of adults with schizophrenia and Sunovion received approval to market the drug.[4] Sunovion then received regulatory FDA approval to market Latuda (lurasidone HCL) as a monotherapy and adjunctive therapy with either lithium or valproate to treat adults with major depressive episodes associated with bipolar I disorder (bipolar depression) in July 2013. [5]'
The sources for this paragraph are https://psychcentral.com/news/2010/10/28/latuda-approved-to-treat-schizophrenia/20351.html and https://www.boston.com/news/innovation/2013/07/03/fda-approves-sunovions-latuda-to-treat-some-cases-of-bipolar-disorder
ThanksEd at Sunovion (talk) 20:03, 30 January 2020 (UTC)
thread_title:  Sunovion - edits